MYCN as a target for cancer immunotherapy

Cancer Immunology, Immunotherapy

Volumn 57, Issue 5, 2008, Pages 693-700

  Himoudi, Nourredine ^a   Yan, Mengyong ^a   Papanastasiou, Antigoni ^a   Anderson, John ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Dendritic cells; Immunotherapy; MYCN; Peptide epitope

Indexed keywords

AMINO ACID; CYCLOSPORIN A; HLA A2 ANTIGEN;

ARTICLE; BLOOD; CANCER IMMUNOTHERAPY; CELL LINE; CYTOTOXIC T LYMPHOCYTE; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MYCN GENE; NEUROBLASTOMA; PRIORITY JOURNAL; TUMOR CELL; TUMOR GENE;

EID: 43149119262     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0409-x     Document Type: Article

References (22)

1. 1. ME Dudley JR Wunderlich JC Yang RM Sherry SL Topalian NP Restifo RE Royal U Kammula DE White SA Mavroukakis LJ Rogers GJ Gracia SA Jones DP Mangiameli MM Pelletier J Gea-Banacloche MR Robinson DM Berman AC Filie A Abati SA Rosenberg 2005 Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma J Clin Oncol 23 2346 2357 15800326 10.1200/JCO.2005.00.240 1:CAS:528:DC%2BD2MXjsVyhsrs%3D Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346–2357
2. 2. ME Dudley SA Rosenberg 2003 Adoptive-cell-transfer therapy for the treatment of patients with cancer Nat Rev Cancer 3 666 675 12951585 10.1038/nrc1167 1:CAS:528:DC%2BD3sXmvVWlu7s%3D Dudley ME, Rosenberg SA (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666–675
3. 3. P Correale K Walmsley C Nieroda S Zaremba M Zhu J Schlom KY Tsang 1997 In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen J Natl Cancer Inst 89 293 300 9048833 10.1093/jnci/89.4.293 1:CAS:528:DyaK2sXhvVegsLo%3D Correale P, Walmsley K, Nieroda C, Zaremba S, Zhu M, Schlom J, Tsang KY (1997) In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 89:293–300
4. 4. L Gao I Bellantuono A Elsasser SB Marley MY Gordon JM Goldman HJ Stauss 2000 Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1 Blood 95 2198 2203 10733485 1:CAS:528:DC%2BD3cXitFeisbs%3D Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM, Stauss HJ (2000) Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95:2198–2203
5. 5. WW Overwijk MR Theoret SE Finkelstein DR Surman LA Jong de FA Vyth-Dreese TA Dellemijn PA Antony PJ Spiess DC Palmer DM Heimann CA Klebanoff Z Yu LN Hwang L Feigenbaum AM Kruisbeek SA Rosenberg NP Restifo 2003 Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells J Exp Med 198 569 580 12925674 10.1084/jem.20030590 1:CAS:528:DC%2BD3sXms1WisL4%3D Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP (2003) Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med 198:569–580
6. 6. RJ Brentjens JB Latouche E Santos F Marti MC Gong C Lyddane PD King S Larson M Weiss I Riviere M Sadelain 2003 Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 Nat Med 9 279 286 12579196 10.1038/nm827 1:CAS:528:DC%2BD3sXhsFGgs7k%3D Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, King PD, Larson S, Weiss M, Riviere I, Sadelain M (2003) Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med 9:279–286
7. 7. DA Morgenstern J Anderson 2006 MYCN deregulation as a potential target for novel therapies in rhabdomyosarcoma Expert Rev Anticancer Ther 6 217 224 16445374 10.1586/14737140.6.2.217 1:CAS:528:DC%2BD28XitVClur0%3D Morgenstern DA, Anderson J (2006) MYCN deregulation as a potential target for novel therapies in rhabdomyosarcoma. Expert Rev Anticancer Ther 6:217–224
8. 8. AK Sarkar JG Nuchtern 2000 Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes Cancer Res 60 1908 1913 10766179 1:CAS:528:DC%2BD3cXisVynu78%3D Sarkar AK, Nuchtern JG (2000) Lysis of MYCN-amplified neuroblastoma cells by MYCN peptide-specific cytotoxic T lymphocytes. Cancer Res 60:1908–1913
9. 9. A Jakobovits M Schwab JM Bishop GR Martin 1985 Expression of N-myc in teratocarcinoma stem cells and mouse embryos Nature 318 188 191 3840574 10.1038/318188a0 1:CAS:528:DyaL28Xhs1Shsg%3D%3D Jakobovits A, Schwab M, Bishop JM, Martin GR (1985) Expression of N-myc in teratocarcinoma stem cells and mouse embryos. Nature 318:188–191
10. 10. KA Zimmerman GD Yancopoulos RG Collum RK Smith NE Kohl KA Denis MM Nau ON Witte D Toran-Allerand CE Gee 1986 Differential expression of myc family genes during murine development Nature 319 780 783 2419762 10.1038/319780a0 1:CAS:528:DyaL28XhsVeisro%3D Zimmerman KA, Yancopoulos GD, Collum RG, Smith RK, Kohl NE, Denis KA, Nau MM, Witte ON, Toran-Allerand D, Gee CE et al (1986) Differential expression of myc family genes during murine development. Nature 319:780–783
11. 11. K Zimmerman E Legouy V Stewart R Depinho FW Alt 1990 Differential regulation of the N-myc gene in transfected cells and transgenic mice Mol Cell Biol 10 2096 2103 2183019 1:CAS:528:DyaK3cXktlGltbY%3D Zimmerman K, Legouy E, Stewart V, Depinho R, Alt FW (1990) Differential regulation of the N-myc gene in transfected cells and transgenic mice. Mol Cell Biol 10:2096–2103
12. 12. I Semsei SY Ma RG Cutler 1989 Tissue and age specific expression of the myc proto-oncogene family throughout the life span of the C57BL/6J mouse strain Oncogene 4 465 471 2470008 1:CAS:528:DyaL1MXktlOjsb0%3D Semsei I, Ma SY, Cutler RG (1989) Tissue and age specific expression of the myc proto-oncogene family throughout the life span of the C57BL/6J mouse strain. Oncogene 4:465–471
13. 13. GM Brodeur RC Seeger M Schwab HE Varmus JM Bishop 1984 Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage Science 224 1121 1124 6719137 10.1126/science.6719137 1:STN:280:BiuC1Mnkt1E%3D Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224:1121–1124
14. 14. AJ Wong JM Ruppert J Eggleston SR Hamilton SB Baylin B Vogelstein 1986 Gene amplification of c-myc and N-myc in small cell carcinoma of the lung Science 233 461 464 3014659 10.1126/science.3014659 1:CAS:528:DyaL28XkslKrt7s%3D Wong AJ, Ruppert JM, Eggleston J, Hamilton SR, Baylin SB, Vogelstein B (1986) Gene amplification of c-myc and N-myc in small cell carcinoma of the lung. Science 233:461–464
15. 15. D Williamson YJ Lu T Gordon R Sciot A Kelsey C Fisher C Poremba J Anderson K Pritchard-Jones J Shipley 2005 Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype J Clin Oncol 23 880 888 15681534 10.1200/JCO.2005.11.078 1:CAS:528:DC%2BD2MXitVKit7Y%3D Williamson D, Lu YJ, Gordon T, Sciot R, Kelsey A, Fisher C, Poremba C, Anderson J, Pritchard-Jones K, Shipley J (2005) Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol 23:880–888
16. 16. JA Garson PG McIntyre JT Kemshead 1985 N-myc amplification in malignant astrocytoma Lancet 2 718 719 2863693 10.1016/S0140-6736(85)92950-2 1:STN:280:BiqB1Mrgslc%3D Garson JA, McIntyre PG, Kemshead JT (1985) N-myc amplification in malignant astrocytoma. Lancet 2:718–719
17. 17. WH Lee AL Murphree WF Benedict 1984 Expression and amplification of the N-myc gene in primary retinoblastoma Nature 309 458 460 6728001 10.1038/309458a0 1:CAS:528:DyaL2cXktFynurw%3D Lee WH, Murphree AL, Benedict WF (1984) Expression and amplification of the N-myc gene in primary retinoblastoma. Nature 309:458–460
18. 18. PD Nisen KA Zimmerman SV Cotter F Gilbert FW Alt 1986 Enhanced expression of the N-myc gene in Wilms’ tumors Cancer Res 46 6217 6222 2430692 1:CAS:528:DyaL2sXivVCitg%3D%3D Nisen PD, Zimmerman KA, Cotter SV, Gilbert F, Alt FW (1986) Enhanced expression of the N-myc gene in Wilms’ tumors. Cancer Res 46:6217–6222
19. 19. BA Malynn IM Alboran de RC O’Hagan R Bronson L Davidson RA DePinho FW Alt 2000 N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation Genes Dev 14 1390 1399 10837031 1:CAS:528:DC%2BD3cXjvFOgtr4%3D Malynn BA, de Alboran IM, O’Hagan RC, Bronson R, Davidson L, DePinho RA, Alt FW (2000) N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. Genes Dev 14:1390–1399
20. 20. S Pelengaris T Littlewood M Khan G Elia G Evan 1999 Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion Mol Cell 3 565 577 10360173 10.1016/S1097-2765(00)80350-0 1:CAS:528:DyaK1MXjslCqurY%3D Pelengaris S, Littlewood T, Khan M, Elia G, Evan G (1999) Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 3:565–577
21. 21. N Himoudi S Nabarro M Yan K Gilmour AJ Thrasher J Anderson 2007 Development of anti-PAX3 immune responses; a target for cancer immunotherapy Cancer Immunol Immunother 56 1381 1395 17318653 10.1007/s00262-007-0294-3 1:CAS:528:DC%2BD2sXntVOlsbw%3D Himoudi N, Nabarro S, Yan M, Gilmour K, Thrasher AJ, Anderson J (2007) Development of anti-PAX3 immune responses; a target for cancer immunotherapy. Cancer Immunol Immunother 56:1381–1395
22. 22. JL Schultze S Michalak MJ Seamon G Dranoff K Jung J Daley JC Delgado JG Gribben LM Nadler 1997 CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy J Clin Invest 100 2757 2765 9389740 1:CAS:528:DyaK2sXotVaqtbg%3D 10.1172/JCI119822 Schultze JL, Michalak S, Seamon MJ, Dranoff G, Jung K, Daley J, Delgado JC, Gribben JG, Nadler LM (1997) CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 100:2757–2765